WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > CAE Healthcare
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Pharma Tech
Warburg Pincus | February 11, 2022
Warburg Pincus, a leading global growth investor, tannounced the acquisition of Pharma Intelligence, a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, from Informa PLC the international B2B markets knowledge services and business intelligence group. Mubadala Investment Company, the Abu Dhabi based investment company, joins Warburg Pincus in the investment. The investors plan to extend the company's leading posi...
Clarus | April 22, 2020
Clarus, the industry leader in glassboard innovation and creator of the new TherMobile, a non-porous mobile board that serves as a protective shield during the health screening process, is successfully supporting AstraZeneca's efforts in keeping their essential employees safe while continuing to work during the COVID-19 crisis. "We initially developed TherMobile as a way to keep our own employees safe while implementing employee temperature screening at our facility," said Marc Man...
Movilitas | September 11, 2020
Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for the Asia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as a service solution (SaaS), and their all-European-made Serialization & Aggregation technologies dedicated to the pharmaceutical industry in the region. Their comprehensive portfolio enables companies to comply with global regulations while imp...
CPD AND LEARNING, VIEWS AND ANALYSIS
prnewswire | June 05, 2023
Jazz Pharmaceuticals plc and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abst...
Pharmacy Market
Whitepaper
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE